Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment

NCT00422981 is registered in ClinicalTrials.gov with Allon Therapeutics as lead sponsor.

NCT NCT00422981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00422981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment
Lead sponsor
Allon Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
January 31, 2008
Enrollment
144 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment, so stated